Lung cancer is one of the most common malignant tumors in the lungs. It is one of the most malignant tumors that threaten human health and life. According to the latest statistics, in 2015, the incidence of new lung cancer in China was about 733 thousand, ranking the first place in the incidence of malignant tumors, of which the incidence of male is two times that of women. At the same time, the death rate of lung cancer in China is about 610 thousand in 2015, which is also the leading cause of cancer mortality.

In histology, lung cancer can be divided into non-small cell lung cancer and small cell lung cancer, of which non small cell lung cancer accounts for more than 85%. Non-small cell lung cancer can be further divided into adenocarcinoma, squamous cell carcinoma and large cell carcinoma. The proportion of adenocarcinoma is the highest, about 2/3 of the primary lung cancer. For different types and different stages of lung cancer, the treatment methods are roughly divided into 4 kinds, namely, surgical treatment, chemotherapy, radiotherapy and targeted therapy.

Scientific research has proved that cancer is caused by genetic variation in human body. These mutations will make cells lose normal regulation ability, and thus will proliferate indefinitely, eventually leading to cancer. Targeted drugs can kill tumor cells carrying specific gene variants and have significant effects. Therefore, they are considered as the first choice for multiple cancer patients. At present, FDA has been approved by the CFDA to the target / lung cancer drugs including Iressa, Tarceva, Camry, Saikerui, afatinib, Shairui imatinib, anowl imatinib and Tagrisso. However, for different patients, the genetic variation carried by them is also varied. This difference results in the sensitivity and toxicity of each patient to the same anti-tumor drugs are not the same.

.

In the US guidelines for cancer diagnosis, the genes related to targeted drug use in non-small cell lung cancer were clearly recommended. Besides the EGFR and ALK gene mutations recommended routinely, five genetic variants including BRAF, MET, RET, ROS1 and HER2 were also included in the recommended detection range. At present, these genetic variants have been commercialized targeting drugs.

Precision diagnosis is a prerequisite for precision medical treatment. The idea of molecular typing enables doctors to develop the best treatment plan according to the biomarkers and corresponding clinical conditions of lung cancer patients, and to find the most potential target drugs and improve the efficiency of anticancer drugs.

The occurrence of tumor is often accompanied by multiple gene mutations and is heterogeneous. As more and more lung cancer target - driven genes are found, the traditional single detection technique is not enough to meet the needs of current detection. The two generation sequencing technology can achieve multi gene parallel detection, and achieve higher technical sensitivity under the condition of more sample saving than traditional detection methods, so as to restore the panoramic panoramic of cancer more realistically.

Detection of individualized drug use gene in lung cancer

Enjoy the medicine oriented with lung cancer, using the two generation sequencing technology advanced, comprehensive detection of non small cell lung cancer NCCN guidelines of drug target for inhibition, II / III clinical trials in the inhibition of target drug development, provide reference information for clinical lung cancer individualized treatment options.

The gene for medical examination

Targeted medicine for medical treatment

Intended for

Sample requirements

Both fresh tissue and paraffin embedded samples were available for both surgical and puncture samples.